Inositol polyphosphate multikinase signaling in the regulation of metabolism

Joo-Young Lee,1 Young-ran Kim,1,2 Jina Park,1 and Seyun Kim1
1Department of Biological Sciences, Korea Advanced Institute of Science and Technology, Daejeon, Korea. 2College of Pharmacy, Chungnam National University, Daejeon, Korea

Address for correspondence: Seyun Kim, Department of Biological Sciences, Korea Advanced Institute of Science and Technology, 291 Daehak-ro, Yuseong-gu, Daejeon 305-701, Korea. seyunkim@kaist.ac.kr

Inositol polyphosphates (IPs) act as signaling messengers to regulate various cellular processes such as growth. Inositol polyphosphate multikinase (IPMK) generates inositol tetrakis- and pentakisphosphates (IP4 and IP5), acting as a key enzyme for inositol polyphosphate biosynthesis. IPMK was initially discovered as an essential subunit of the arginine-sensing transcription complex in budding yeast. In mammals, IPMK is also known as a physiologically important phosphatidylinositol 3 kinase (PI3K) that forms phosphatidylinositol 3,4,5-trisphosphate (PIP3), which activates Akt/PKB and stimulates its signaling. Acting in a catalytically independent fashion, IPMK mediates the activation of mammalian target of rapamycin (mTOR) in response to essential amino acids. In addition, IPMK binds and modulates AMP-activated protein kinase (AMPK) signaling pathways, including those involved in hypothalamic control of food intake. These recent findings strongly suggest that IPMK is a versatile player in insulin-, nutrient-, and energy-mediated metabolism signaling networks. Agents that control IPMK functions may provide novel therapeutics in metabolic syndromes such as obesity and diabetes.

Keywords: inositol polyphosphate; IPMK; mTOR; AMPK; growth; metabolism

Introduction

Inositol is a naturally occurring glucose isomer and a key nutrient in the human diet.1 Myo-inositol, a six-carbon cyclitol that contains one axial and five equatorial hydroxyl groups, is the major form of nine possible inositol isomers. Inositol was formerly assumed to be an essential B complex vitamin; however, inositol is now known to be synthesized de novo in the human body. For instance, one normal adult kidney can produce a few grams of inositol per day.2 Inositol is converted from glucose-6-phosphate (G6P) through two biochemical reactions: G6P is first isomerized by inositol 3-phosphate synthase to inositol 3-phosphate, which is dephosphorylated by inositol monophosphatase 1 to yield free myo-inositol. In plants, inositol hexakisphosphate (IP6) is known as phytic acid, which is enriched in cereals and is utilized for phosphorus storage. When the levels of inositol become extremely low, severe medical disturbances, such as diabetic changes, anxiety disorders, and hypercholesterolemia ensue.1,3

Aside from a structural role for inositol (in the form of phosphatidylinositol) in maintaining the cellular membrane bilayer, inositol is viewed as a secondary signaling messenger that controls diverse physiologic events.4–6 The best characterized signaling function for inositol polyphosphate, defined as an inositol harboring more than one phosphate, is inositol 1,4,5-trisphosphate (IP3)-mediated cytosolic calcium release.7,8 Upon growth factor stimulation, activated phospholipases hydrolyze phosphatidylinositol 4,5-bisphosphates (PIP2) into water-soluble IP3 and lipid-anchored diacylglycerol. IP3 then binds to the IP3 receptor, which is localized on the membranes of intracellular calcium storage sites such as the endoplasmic reticulum, and subsequently elevates cytosolic calcium levels by stimulating the calcium channel activity of the IP3 receptor. Since the discovery of IP3 and its signaling role in the mid-1980s, continuing...
investigations of the biochemical fate of IP₃ inside the cell have revealed the presence of a family of inositol phosphate kinases and associated specific phosphorylation events on the inositol ring at different hydroxyl groups (Fig. 1). Higher inositol polyphosphates include inositol pyrophosphates (e.g., IP₇), which contain diphosphates with one or more high energy-harboring pyrophosphate bonds. Multiple approaches, including genetic manipulation of inositol polyphosphate metabolism and biochemical characterization of IP-binding signaling targets, have recently highlighted the physiologic significance of inositol poly- and pyrophosphates in the regulation of major physiologic events such as growth and apoptosis (reviewed in Ref. 4). In this review, we will focus on inositol polyphosphate multikinase (IPMK) and its signaling functions in controlling mammalian target of rapamycin (mTOR) and adenosine monophosphate (AMP)-activated protein kinase (AMPK), two major central molecules in metabolism signaling networks.

**IPMK and IP metabolism**

In the process of cloning of IP₄ kinase genes, Snyder and his associates identified IPRMK as an enzyme essential for the synthesis of IP₄ (both Ins(1,3,4,5)P₄ and Ins(1,4,5,6)P₄) and IP₅ (Ins(1,3,4,5,6)P₅).⁹,¹⁰ In organisms from yeast to humans, IPRMK is often the only enzyme responsible for converting IP₄ into IP₅. Thus, IPRMK deletion abolishes the formation of IP₅, but it also eliminates IP₆ and IP₇ formation, indicating that IPRMK is an essential enzyme in the generation of all highly phosphorylated IP species, including IP₇.¹¹,¹² Its unique broad substrate specificity also enables IPRMK to operate as a lipid-soluble inositol kinase that can phosphorylate PIP₂ at the 3 position to produce phosphatidylinositol 3,4,5-trisphosphate (PIP₃) (Fig. 1).¹³,¹⁴ IPRMK deletion in mouse embryonic fibroblast results in a 50% decrease in PIP₃ levels as well as significantly reduced PIP₃-dependent Akt signaling in response to growth stimuli such as insulin and epidermal growth factor.
suggesting that IPMK functions physiologically as a PI3 kinase.

**Yeast IPMK and arginine metabolism**

Possible IPMK functions in mammalian metabolic homeostasis were suggested by previous studies in budding yeast designed to screen for genes that regulate metabolic activities in response to arginine availability. IPMK was initially cloned as Arg82/ArgRIII, one of the proteins involved in the regulation of arginine metabolism, and is now designated Ipk2 or yeast IPMK. Arg80-Mcm1 is an arginine-sensing transcriptional complex that governs the expression of genes required for arginine metabolism. Yeast IPMK, acting independently of its catalytic activity, is crucial for assembling the Arg80-Mcm1 protein complex at the promoter region of genes involved in arginine metabolism. However, the kinase activity of yeast IPMK and production of inositol polyphosphates are also required for the appropriate stimulation of the Arg80-Mcm1 transcription complex, as demonstrated in phenotypic cell growth assays. Restoration of the IPMK products, IP4 and IP5, by overexpressing the IPMK gene from evolutionarily divergent plant or fruit fly functionally rescues the growth defect in IPMK-null yeast cells.

**IPMK and mTOR signaling**

Among the many factors that contribute to the regulation of anabolic pathways (e.g., protein synthesis) in mammals by growth factors and nutrients such as essential amino acids, the mTOR complex 1 (mTORC1) is considered to be a central signaling regulator (reviewed in Ref. 20). mTOR is a serine/threonine protein kinase that exists as two distinct protein complexes; mTORC1 is defined by an association of mTOR with the binding proteins raptor, PRAS40, DEPTOR, and mLST8, whereas the integrity of mTORC2 depends on rictor, Protor, mSIN1, DEPTOR, and mLST8. The rapamycin-sensitive mTORC1 complex promotes anabolic reactions such as protein synthesis and inhibits autophagy, whereas the rapamycin-insensitive mTORC2 complex exerts discrete functions as an Akt serine 473 kinase. Signaling pathways by which insulin and other growth factors stimulate mTORC1 have been well delineated. Growth factors act through PIP3 to activate the PI3K pathway, which stimulates protein kinase Akt/PKB. Activative Akt, in turn, phosphorylates TSC2, abrogating TSC2-mediated inhibition of Rheb GTPase, which can directly stimulate mTORC1. The entire process by which nutrient amino acids activate mTORC1 has remained elusive. However, a growing body of evidence clearly suggests that in response to amino acids, Rag GTPases, in association with the Regulator complex, mediates the spatial redistribution of inactive mTORC1 to the surface of lysosomes, which contain mTOR-activating Rheb GTPase. How these molecular events are controlled to promote mTORC1 activation and protein translation is largely unknown, although the vacuolar H(+)-adenosine triphosphatase ATPase and leucyl-tRNA synthetase have been recently discovered as essential factors for amino-acid sensing.

In searching for roles of IPMK in mammalian metabolic signaling systems, Kim et al. identified IPMK as a novel mTOR cofactor and a critical determinant of amino acid-induced mTORC1 signaling. Deletion of IPMK in mouse embryonic fibroblasts markedly reduces both amino acid-stimulated mTORC1 activation and leucine-induced cell growth, effects comparable to the deletion of raptor, an essential subunit of mTORC1-signaling responses to essential amino acids. Interestingly, a catalytically incompetent IPMK mutant stimulates mTORC1 as effectively as wild-type IPMK. The fact that selective and significant disruption of mTOR binding to raptor does not produce a defect in mTORC2 stability led to the discovery of IPMK as a novel cofactor for mTORC1 signaling. Mammalian IPMK genes contain a unique amino terminal domain indispensable for the regulation of IPMK-dependent mTORC1-signaling responses to amino acids. This mammalian-specific amino terminus of IPMK mediates direct binding of IPMK with mTOR. Overexpression of the amino terminal 60 amino acids of IPMK in HEK293 cells selectively interrupts endogenous mTOR-raptor interactions in the presence of amino acids and inhibits amino acid-induced mTORC1 signaling. Taken together, these observations suggest that IPMK is a physiologic cofactor of mTOR, maintaining mTORC1 stability and thereby mediating the ability of amino acids to fully activate mTORC1. Presumably, IPMK has evolved from a scaffolding protein that assembles the arginine sensor in budding yeast to a cytosolic,
Figure 2. Multiple actions of IPMK in metabolism signaling networks. In response to insulin stimulation, IPMK acts as a PI3 kinase to produce PIP3 and thus activate Akt. As an IP kinase, IPMK also generates IP4 and IP5, precursors of inositol poly- and pyrophosphates. IP6K1-dependent 5-IP7 inhibits Akt activation, thereby negatively regulating downstream insulin actions such as adipogenesis. Acting in a catalytic activity-independent manner, IPMK binds, stabilizes, and mediates the activation of mTORC1 in response to amino acids. The kinase activity of IPMK appears to mediate insulin-dependent mTORC2 activation, but the detailed molecular mechanisms remain unclear. Another IPMK signaling target is AMPK, which governs central metabolic homeostasis by controlling food intake. The binding of IPMK to AMPK appears to be the key event in the modulation of AMPK signaling by upstream AMPK kinases or protein phosphatases.

mTOR-associated factor that mediates the stable interaction between mTOR and raptor in mammalian cells.12,26

IPMK and AMPK signaling

AMPK is an evolutionarily conserved energy sensor that triggers catabolic energy fluxes and antagonizes ATP-consuming anabolic pathways.27 AMPK is composed of a catalytic (α) subunit and two regulatory (β, γ) subunits. The γ subunit contains two regions that bind energy metabolites (i.e., AMP, ADP, and ATP), in an antagonistic fashion to regulate AMPK activity under energy-stress conditions. Activation of AMPK requires phosphorylation of the α subunit. The activity of AMPK is also controlled by upstream kinases such as liver kinase B1 (LKB1).28 Calmodulin-dependent protein kinase kinase-beta (CAMKKβ) is another kinase that activates AMPK under conditions of high cytosolic calcium levels.29 AMPK phosphorylates a variety of substrates to alter diverse cellular functions, including fatty acid synthesis/oxidation, glycolysis, mitochondrial biogenesis, and gluconeogenesis. Besides controlling carbohydrate and lipid metabolism, AMPK phosphorylates major mTOR-signaling regulators like TSC2, thus functioning to suppress mTOR signaling that governs anabolic responses, such as protein synthesis. In particular, AMPK signaling in the hypothalamus, a main metabolic tissue in the central nervous system, has been shown to control whole-body energy metabolism (i.e., feeding behavior) by integrating physiologic signals from hormones and nutrients.30,31

Bang and Kim et al. recently demonstrated that IPMK’s function in regulating cellular metabolism is not limited to mTOR, but is further extended to hypothalamic AMPK.32 Hypothalamic IPMK mRNA and protein levels dynamically respond to energy conditions, such that hypothalamic IPMK levels are downregulated in fasted mice but are markedly elevated upon refeeding. Conditional deletion of the hypothalamic IPMK gene in the arcuate nucleus by adenoviral-mediated introduction of Cre recombinase into the floxed-IPMK gene, in mouse brain, aberrantly increases hypothalamic AMPK signaling activity under ad libitum conditions. Similarly, IPMK gene deletion in mouse embryonic fibroblasts produces AMPK signaling defects accompanied by the loss of dynamic regulation of AMPK activity in response to glucose availability.

IPMK appears to be a novel AMPK-binding protein whose binding affinity for AMPK is dynamically controlled by glucose level.32 Glucose-starvation in cell culture settings reduces the IPMK-AMPK
interaction, which is recovered by glucose treatment. Glucose induces IPMK phosphorylation at tyrosine-174 (IPMK-Y174), which enhances IPMK-AMPK binding and AMPK signaling responses to glucose. Overexpression of dominant-negative IPMK peptides interrupts the binding of IPMK with AMPK and disrupts dynamic AMPK signaling responses to glucose levels. Under energy-stress conditions, the levels of the IPMK-Y174 phosphorylated form are lower, IPMK-AMPK binding is decreased, and AMPK is phosphorylated by LKB1. Glucose stimulation induces phosphorylation of IPMK-Y174 and enhances the interaction between IPMK and AMPK, thereby presumably interrupting LKB1 function and thus modulating AMPK signaling.

A physiological role for hypothalamic IPMK in the control of AMPK signaling and related central energy homeostasis functions was further explored by examining the effects of IPMK deletion within the arcuate nucleus on AMPK signaling and food intake under fasting and refeeding conditions. Interestingly, compared to controls, the levels of phospho-AMPK signal, as well as the amount of food consumption, are significantly decreased in mice with a specific deletion of the IPMK gene in the arcuate nucleus. These findings strongly suggest that AMPK dephosphorylation and associated anorexic behavior are enhanced in the absence of IPMK. Loss of IPMK in the arcuate nucleus apparently enables AMPK to become a susceptible target for an AMPK-specific protein phosphatase; as a result, AMPK is rapidly inactivated. These data clearly support a new physiological role for hypothalamic AMPK signaling and food intake.

**Conclusions**

A growing body of evidence suggests the functional significance of IPMK in the regulation of metabolism signaling networks in response to hormones (e.g., insulin), amino acids, and energy levels (Fig. 2). Despite substantial advances in understanding the physiological functions of IPMK, many questions regarding the mechanistic details of IPMK actions remain unanswered. For example, what stoichiometric relationships between IPMK and its multiple signaling targets (e.g., mTOR and AMPK) are possible? And what is the glucose-regulated protein tyrosine kinase that mediates IPMK phosphorylation and associated IPMK signaling?

Importantly, IPMK is directly or indirectly involved in other major cellular events, such as gene expression and apoptosis. In conjunction with IP6K, the IP kinase activity of IPMK plays a critical role in generating IP7 (Fig. 1), which is either an Akt inhibitor or a regulator of p53-mediated apoptosis, depending on cellular context. On the other hand, the PI3 kinase activity of IPMK, acting in concert with the classical p85/p110-PI3K, is responsible for growth factor-stimulation of Akt signaling. Future studies on how the PI3 kinase, IP kinase, and/or kinase activity-independent signaling functions of IPMK can be switched on or off may reveal a crucial mechanism of IPMK regulation. Presumably, the two major catalytic roles of IPMK work coordinately with the noncatalytic actions of IPMK in mediating responses of mTORC1 to amino acids.

Another major area of future IPMK research is to identify novel IPMK functions in metabolism or related signaling pathways. Recent reports on an unexpected role for IP4, one of the products of IPMK, in the assembly and activation of histone deacetylase complexes clearly suggests the presence of additional targets of IPMK-mediated epigenetic signaling in mammalian cells. The nucleocytoplasmic shuttling of IPMK and the identification of the nuclear receptor steroidogenic factor 1 as a new IPMK target also indicate the complexity of IPMK signaling actions. Studies of tissue- or cell-type–specific IPMK functions using conditional gene knockout strategies may help to elucidate the physiological roles of IPMK in vivo. Because IPMK regulates Akt and mTOR in cell culture settings, we speculate that IPMK-null organs in mouse model systems may exhibit attenuated insulin responses and related metabolic changes affecting glucose homeostasis and adipogenesis. IPMK-mediated AMPK signaling also provides another potential regulatory layer critical for allowing target tissues and the whole body to accurately gauge and adapt energy and nutrient levels. The question of how multiple IPMK signaling functionalities integrate different types of upstream metabolic stimuli warrants further investigation. Accordingly, drugs that perturb IPMK signaling actions on major metabolic signaling targets, such as Akt, mTOR, and AMPK, may have therapeutic applications for metabolic syndromes (e.g., insulin resistance, diabetes, obesity).
obesity, type 2 diabetes) and related eating disorders, such as bulimia and anorexia nervosa.

Acknowledgments
This work was supported by the Brain Korea 21 Project.

Conflicts of interest
The authors declare no conflicts of interest.

References
1. Holub, B.J. 1986. Metabolism and function of myo-inositol and inositol phospholipids. Annu. Rev. Nutr. 6: 563–597.
2. Troyer, D.A., D.W. Schwertz, J.I. Kreisberg & M.A. Venkatachalam. 1986. Inositol phospholipid metabolism in the kidney. Annu. Rev. Physiol. 48: 51–71.
3. Colodny, L. & R.L. Hoffman. 1998. Inositol-clinical applications for exogenous use. Altern. Med. Rev. 3: 432–447.
4. Chakraborty, A., S. Kim & S.H. Snyder. 2011. Inositol pyrophosphates as mammalian cell signals. Sci. Signal. 4: re1.
5. Hatch, A.J. & J.D. York. 2010. SnapShot: inositol phosphates. Cell 143: 1030–1030.e1.
6. Barker, C.J., C. Illies, G.C. Gaboardi & P.O. Berggren. 2009. Inositol pyrophosphates: structure, enzymeology and function. Cell Mol. Life Sci. 66: 3851–3871.
7. Streb, H., R.F. Irvine, M.J. Berridge & I. Schulz. 1983. Release of Ca2+ from a nonmitochondrial intracellular store in pancreatic acinar cells by inositol-1,4,5-trisphosphate. Nature 306: 67–69.
8. Berridge, M.J., P. Lipp & M.D. Bootman. 2000. The versatility and universality of calcium signalling. Nat. Rev. Mol. Cell Biol. 1: 11–21.
9. Saiardi, A., H. Erdjument-Bromage, A.M. Snowman, et al. 1999. Synthesis of diphosphoinositolpentakisphosphate by a newly identified family of higher inositol polyphosphate kinases. Curr. Biol. 9: 1323–1326.
10. Odom, A.R., A. Stahlberg, S.R. Wente & J.D. York. 2000. A role for nuclear inositol 1,4,5-trisphosphate kinase in transcriptional control. Science 287: 2026–2029.
11. Frederick, J.P., D. Mattiske, J.A. Woford, et al. 2000. An essential role for an inositol polyphosphate multikinase, Ipk2, in mouse embryogenesis and second messenger production. Proc. Natl. Acad. Sci. USA 102: 8454–8459.
12. Kim, S., S.F. Kim, D. Maag, et al. 2011. Amino acid signaling to mTOR mediated by inositol polyphosphate multikinase. Cell Metab. 13: 215–221.
13. Resnick, A.C., A.M. Snowman, B.N. Kang, et al. 2005. Inositol polyphosphate multikinase is a nuclear PI3-kinase with transcriptional regulatory activity. Proc. Natl. Acad. Sci. USA 102: 12783–12788.
14. Maag, D., M.J. Maxwell, D.A. Hardesty, et al. 2011. Inositol polyphosphate multikinase is a physiologic PI3-kinase that activates Akt/PKB. Proc. Natl. Acad. Sci. USA 108: 1391–1396.
15. Béchet, J., M. Grenson & J.M. Wiame. 1970. Mutations affecting the repressibility of arginine biosynthetic enzymes in Saccharomyces cerevisiae. Eur. J. Biochem. 12: 31–39.
16. Dubois, E., V. Dewaste, C. Erneux & F. Messenguy. 2000. Inositol polyphosphate kinase activity of Arg82/ArgRIII is not required for the regulation of the arginine metabolism in yeast. FEBS Lett. 486: 300–304.
17. El Alami, M., F. Messenguy, B. Scherens & E. Dubois. 2003. Arg82p is a bifunctional protein whose inositol polyphosphate kinase activity is essential for nitrogen and PHO gene expression but not for Mcm1p chaperoning in yeast. Mol. Microbiol. 49: 457–468.
18. Seeds, A.M., R.J. Bastidas & J.D. York. 2005. Molecular definition of a novel inositol polyphosphate metabolic pathway initiated by inositol 1,4,5-trisphosphate 3-kinase activity in Saccharomyces cerevisiae. J. Biol. Chem. 280: 27654–27661.
19. John, D. & J.D. York. 2006. Regulation of nuclear processes by inositol polyphosphates. Biochim. Biophys. Acta 1761: 552–559.
20. Zoncu, R., A. Efeyan & D.M. Sabatini. 2011. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell Biol. 12: 21–35.
21. Sancak, Y., T.R. Peterson, Y.D. Shaul, et al. 2008. The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science 320: 1496–1501.
22. Kim, E., P. Goraksha-Hicks, L. Li, et al. 2008. Regulation of TORC1 by Rag GTPases in nutrient response. Nat. Cell Biol. 10: 935–945.
23. Sancak, Y., L. Bar-Peled, R. Zoncu, et al. 2010. Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids. Cell 141: 290–303.
24. Zoncu, R., L. Bar-Peled, A. Efeyan, et al. 2011. mTORC1 senses lysosomal amino acids through an inside-out mechanism that requires the vacuolar H(+)-ATPase. Science 334: 678–683.
25. Han, J.M., S.J. Jeong, M.C. Park, et al. 2012. Leucyl-tRNAsynthetase is an intracellular leucine-sensor for the mTORC1-signaling pathway. Cell 149: 410–424.
26. Kim, S. & S.H. Snyder. 2011. Nutrient amino acids signal to mTOR via inositol polyphosphate multikinase. Cell Cycle 10: 1708–1710.
27. Hardie, D.G., F.A. Ross & S.A. Hawley. 2012. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat. Rev. Mol. Cell Biol. 13: 251–262.
28. Alessi, D.R., K. Sakamoto & J.R. Bayascas. 2006. LKB1-dependent signaling pathways. Ann. Rev. Biochem. 75: 137–163.
29. Hawley, S.A., D.A. Pan, K.J. Mustard, et al. 2005. Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for AMP-activated protein kinase. Cell Metab. 2: 9–19.
30. Minokoshi, Y., T. Alquier, N. Furukawa, et al. 2004. AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature 428: 569–574.
31. Andersson, U., K. Filipsson, C.R. Abbott, et al. 2004. AMP-activated protein kinase plays a role in the control of food intake. J. Biol. Chem. 279: 12005–12008.
32. Bang, S., S. Kim, M.J. Dailey, et al. 2012. AMP-activated protein kinase is physiologically regulated by inositol polyphosphate multikinase. Proc. Natl. Acad. Sci. USA 109: 616–620.
33. Dailey, M.J. & S. Kim. 2012. Inositol polyphosphate multikinase: an emerging player for the central action of
AMP-activated protein kinase. *Biochem. Biophys. Res. Commun.* 421: 1–3.

34. Chakraborty, A., M.A. Koldobskiy, N.T. Bello, *et al.* 2010. Inositol pyrophosphates inhibit Akt signaling, thereby regulating insulin sensitivity and weight gain. *Cell* 143: 897–910.

35. Koldobskiy, M.A., A. Chakraborty, J.K. Werner, *et al.* 2010. p53-mediated apoptosis requires inositol hexakisphosphate kinase-2. *Proc. Natl. Acad. Sci. USA* 107: 20947–20951.

36. Watson, P.J., L. Fairall, G.M. Santos & J.W. Schwabe. 2012. Structure of HDAC3 bound to co-repressor and inositol tetraphosphate. *Nature* 481: 335–340.

37. Meyer, R., M.M. Nalaskowski, P. Ehm, *et al.* 2012. Nucleocytoplasmic shuttling of human inositol phosphate multikinase is influenced by CK2 phosphorylation. *Biol. Chem.* 393: 149–160.

38. Blind, R.D., M. Suzawa & H.A. Ingraham. 2012. Direct modification and activation of a nuclear receptor-PIP2 complex by the inositol lipid kinase IPMK. *Sci. Signal.* 5: ra44.